Vioxx was easier on the stomach than aspirin, but it cost more. The FDA safety officer in charge of the report, David Graham, concluded that Vioxx posed much greater cardiovascular risk than the other major drug in its class, Celebrex. ``There was so much denial over there,'' said David Moskowitz, senior pharmaceutical analyst for Friedman, Billings, Ramsey Co. Last week, Gilmartin and Kim still said that none of the earlier Vioxx studies, by either the company or others, convincingly showed increased heart and stroke risk from the drug. I couldn't see Merck saying we're going to market a drug with a safety problem. "When there are other alternatives, why risk trying to use the drug that might have elevated risk?